BUZZ-Celldex shares fall after it drops skin disease drug study
CLDX•Celldex stops development of barzolvolimab for prurigo nodularis
** Drug developer Celldex's shares CLDX.O fall 6.3% to $33.42 in extended trading
** Co says it will discontinue development of experimental drug barzolvolimab for prurigo nodularis, a chronic skin disease
** Barzolvolimab failed to meet the main goal and key secondary goals in a mid-stage study
** As of Tuesday's close, stock has risen ~31% YTD
